Somewhat Positive Press Coverage Somewhat Unlikely to Impact Spring Bank Pharmaceuticals (SBPH) Stock Price
Media stories about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.804438865537 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Spring Bank Pharmaceuticals (NASDAQ SBPH) opened at 14.56 on Friday. Spring Bank Pharmaceuticals has a one year low of $6.31 and a one year high of $16.97. The company’s market cap is $184.87 million. The company has a 50-day moving average of $13.54 and a 200 day moving average of $11.78.
A number of research analysts have recently weighed in on the stock. JMP Securities assumed coverage on shares of Spring Bank Pharmaceuticals in a report on Friday, May 19th. They set a “market perform” rating and a $20.00 price target on the stock. Dawson James restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. Chardan Capital cut their price target on shares of Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, August 1st. ValuEngine downgraded shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Finally, Cantor Fitzgerald assumed coverage on shares of Spring Bank Pharmaceuticals in a report on Wednesday, July 19th. They set an “overweight” rating and a $29.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Spring Bank Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $26.33.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Spring Bank Pharmaceuticals (SBPH) Stock Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-spring-bank-pharmaceuticals-sbph-stock-price/1535873.html.
In other news, Director David Arkowitz purchased 2,500 shares of the business’s stock in a transaction on Friday, August 4th. The stock was purchased at an average price of $12.24 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the director now directly owns 17,086 shares in the company, valued at approximately $209,132.64. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kurt M. Eichler purchased 76,923 shares of the business’s stock in a transaction on Tuesday, June 27th. The stock was purchased at an average price of $13.00 per share, with a total value of $999,999.00. Following the purchase, the director now owns 582,533 shares of the company’s stock, valued at $7,572,929. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 81,423 shares of company stock valued at $1,055,319. Corporate insiders own 17.60% of the company’s stock.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.